May 22, 2023

OAKLAND, Calif. (SynBioBeta 2023, booth 59) - May 22, 2023: GenScript Biotech Corporation has launched GenTitan™ Gene Fragments synthesis service, the world's first and only commercial miniature semiconductor platform that utilizes integrated circuits for high-throughput DNA synthesis. With this technology, GenScript offers top-notch gene fragments synthesis service with the highest gene sequence acceptance rate and the lowest price on the market. The new service will enable scientists from academia and industry to obtain fast and large-scale synthetic DNA for their studies, accelerating progress in the field of synthetic biology, protein and antibody research, metabolism studies, genomic research, virology, and immunology.

Designed for scientists working on biological drug discovery, next-generation sequencing (NGS), and more, the GenTitan™ Gene Fragments synthesis service provides high-quality, double-stranded DNA fragments of up to 1,800 base pairs in length, ideal for gene construction or modification. Especially the researchers who focused on antibody-drug screening and discovery are increasingly seeking larger-scale gene fragments, and high-throughput GenTitan™ Gene Fragments synthesis service is GenScript's response to that need.

Powered by significant innovations in GenScript's miniature semiconductor chip (MSC) technology, the GenTitan sets new industry benchmarks in three key areas:

“GenScript's new site in Zhenjiang is poised to offer unparalleled support and address the increasing demand for oligonucleotide and peptide synthesis — serving the areas such as molecular diagnostics, RNA and peptide drug development, vaccine development, gene editing by providing faster, more reliable, and more cost-effective solutions via our cutting-edge platforms at different scales,” said Dr. Ray Chen, president of the Life Science Group at GenScript.

• Affordability: The proprietary MSC-empowered DNA synthesis technology guarantees the lowest price on the market.
• Acceptance rate: GenScript accepts challenging sequences with confidence. GenTitan™ Gene Fragments synthesis service has the highest complex sequence acceptance rate compared with its competitors.
• Error rate: With over 20 years of gene synthesis experience and the advanced MSC technology, GenScript provides gene fragments with a consistently low error rate, which significantly maximizes screening efficiency and accelerates discovery, saving time and cost.

“Recent supply chain disruptions have limited access to fast-turnaround, high-quality DNA for scientific studies — and there’s no doubt that this has impeded progress in many areas,” said Cedric Wu, VP of GenScript’s Innovation Center. “GenScript’s new GenTitan™ scalable dsDNA platform addresses this issue with a fast-turnaround and high-fidelity gene fragment service, delivering from 200 bp to 1,800 bp at the lowest market cost. We believe GenTitan will open up new possibilities for researchers, allowing them to obtain the fast and high-quality DNA they need to advance biomedical research.”

Utilizing proprietary MSC technology, the industry's highest-density chip for oligo synthesis boasts an astounding 8.4 million unique electrodes at over 2.5 million per square centimeter density. With four chips running in parallel, a staggering 6.7 billion base pairs of DNA can be synthesized in just two days, allowing for unprecedented throughput, speed, and accuracy. Not only has this technology demonstrated its potential in Synthetic DNA storage, but it has also facilitated the construction of the highest-complexity DNA library and high-throughput gene fragment manufacturing plant in the US.

To learn more detailed information about pricing, turnaround time, and quality control measures of GenScript's GenTitan™ Gene Fragments synthesis service, visit their service page at www.genscript.com/gentitan-gene-fragments.html.

About GenScript Biotech Corporation

GenScript Biotech Corporation (HK:1548) is the world’s leading technology and service provider of life-science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech comprises four major platforms: the life-science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform, and the industrial synthesis biological product platform.

GenScript Biotech was founded in New Jersey, United States in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech’s business operations span over 100 countries and regions worldwide with legal entities located in the USA, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript Biotech provides premium, convenient, and reliable services and products for more than 200,000 customers.

As of June 30, 2022, GenScript Biotech had more than 5,500 employees globally, over 38% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 190 patents, over 820 pending patent applications, and numerous trade secrets.

Driven by the corporate mission of “make people and nature healthier through biotechnology,” GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30, 2022, 74,700 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products.

For more information, please visit GenScript Biotech’s official website genscript.com.

Media Contacts